Dermatology’s growing focus on skin longevity demands clear definitions, validated outcomes, and rigorous evidence beyond anti-aging claims.
|Videos|January 28, 2021
Treating COVID-19 Vaccine Reactions in Dermal Filler Patients
Author(s)Morgan Petronelli
In part 4 of our interview with Whitney Bowe, MD, she dives into the multiple methods physicians can use to treat adverse reactions from the COVID-19 vaccine in their dermal filler patients.
Advertisement
Watch part 1 of the interview
Advertisement
Related to this article
Castor oil has become a popular social media remedy for thicker, longer hair, but evidence supporting its ability to stimulate hair growth remains limited.
Can “Botox in a bottle” really rival injectable neuromodulators? We examine the evidence behind topical peptide serums and Argireline.
Tina Bhutani-Jacques, MD, explored how disease location, prior treatment response, and patient preference shape topical treatment decisions across 3 plaque psoriasis cases.
Benjamin Ungar, MD, moderated a recent Dermatology Times Case-Based Roundtable event on how to define severity, choose among JAK inhibitors, and monitor patients with alopecia areata.
Clinicians at a Dermatology Times Case-Based Roundtable, moderated by Chesahna Kindred, MD, debated when to escalate to oral JAK inhibitors for alopecia areata and how to counsel patients on timing, monitoring, and safety.
The joint AAD-HSF guideline issues 37 recommendations, including strong support for adalimumab, bimekizumab, infliximab, and secukinumab.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
Advertisement
Advertisement
Trending on Dermatology Times
1
AAD, HS Foundation Issue First Joint Hidradenitis Suppurativa Guidelines
2
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
3
Individualizing Systemic Therapy for Alopecia Areata Across Patient Cases
4
Skin Longevity Needs Evidence, Not Hype
5